BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38148611)

  • 1. Nuclear-Targeting Lipid Pt
    Wei D; Fan J; Yan J; Liu C; Cao J; Xu C; Sun Y; Xiao H
    J Am Chem Soc; 2024 Jan; 146(1):1185-1195. PubMed ID: 38148611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alendronate Pt
    Sun K; Yuan L; Chen S; Sun Y; Wei D
    Adv Healthc Mater; 2024 Mar; 13(7):e2302746. PubMed ID: 37988194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nano-assembly of ursolic acid with platinum prodrug overcomes multiple deactivation pathways in platinum-resistant ovarian cancer.
    Wang Y; Luo Z; Zhou D; Wang X; Chen J; Gong S; Yu Z
    Biomater Sci; 2021 Jun; 9(11):4110-4119. PubMed ID: 33949442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device.
    Dhar S; Liu Z; Thomale J; Dai H; Lippard SJ
    J Am Chem Soc; 2008 Aug; 130(34):11467-76. PubMed ID: 18661990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Polymeric Nanoparticle to Co-Deliver Mitochondria-Targeting Peptides and Pt(IV) Prodrug: Toward High Loading Efficiency and Combination Efficacy.
    Yang J; Yang Z; Wang H; Chang Y; Xu JF; Zhang X
    Angew Chem Int Ed Engl; 2024 Apr; 63(18):e202402291. PubMed ID: 38380542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A red-light activatable and mitochondrion-targeting Pt
    Li Y; Wang Z; Qi Y; Tang Z; Li X; Huang Y
    Chem Commun (Camb); 2022 Jul; 58(60):8404-8407. PubMed ID: 35796077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs.
    Ravera M; Gabano E; Zanellato I; Bonarrigo I; Alessio M; Arnesano F; Galliani A; Natile G; Osella D
    J Inorg Biochem; 2015 Sep; 150():1-8. PubMed ID: 26042542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Iron Oxide Nanocarrier Loaded with a Pt(IV) Prodrug and Immunostimulatory dsRNA for Combining Complementary Cancer Killing Effects.
    Hernández-Gil J; Cobaleda-Siles M; Zabaleta A; Salassa L; Calvo J; Mareque-Rivas JC
    Adv Healthc Mater; 2015 May; 4(7):1034-42. PubMed ID: 25846677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy.
    Yang GG; Pan ZY; Zhang DY; Cao Q; Ji LN; Mao ZW
    ACS Appl Mater Interfaces; 2020 Sep; 12(39):43444-43455. PubMed ID: 32883070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Anticancer Pt
    Kostrhunova H; Petruzzella E; Gibson D; Kasparkova J; Brabec V
    Chemistry; 2019 Apr; 25(20):5235-5245. PubMed ID: 30740808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-targeting platinum(IV) amphiphilic prodrug nano-assembly as radiosensitizer for synergistic and safe chemoradiotherapy of hepatocellular carcinoma.
    Xiao X; Wang Y; Chen J; Qin P; Chen P; Zhou D; Pan Y
    Biomaterials; 2022 Oct; 289():121793. PubMed ID: 36126545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fabricating nanoparticles co-loaded with survivin siRNA and Pt(IV) prodrug for the treatment of platinum-resistant lung cancer.
    Ma S; Li X; Ran M; Ji M; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X
    Int J Pharm; 2021 May; 601():120577. PubMed ID: 33839227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
    Wang Z; Xu Z; Zhu G
    Angew Chem Int Ed Engl; 2016 Dec; 55(50):15564-15568. PubMed ID: 27736029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
    Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
    Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BODI-Pt, a Green-Light-Activatable and Carboplatin-Based Platinum(IV) Anticancer Prodrug with Enhanced Activation and Cytotoxicity.
    Yao H; Chen S; Deng Z; Tse MK; Matsuda Y; Zhu G
    Inorg Chem; 2020 Aug; 59(16):11823-11833. PubMed ID: 32799491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MOF-based nanozyme grafted with cooperative Pt(IV) prodrug for synergistic anticancer therapy.
    Wu PH; Cheng PF; Kaveevivitchai W; Chen TH
    Colloids Surf B Biointerfaces; 2023 May; 225():113264. PubMed ID: 36921426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reaction of human telomeric unit TTAGGG and a photoactivatable Pt(IV) anticancer prodrug.
    Lin J; Zhang J; Ma Z; Wu X; Wang F; Zhao Y; Wu K; Liu Y
    Dalton Trans; 2023 Aug; 52(34):12057-12066. PubMed ID: 37581306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photoinduced Reduction of Novel Dual-Action Riboplatin Pt(IV) Prodrug.
    Krasnovskaya OO; Akasov RA; Spector DV; Pavlov KG; Bubley AA; Kuzmin VA; Kostyukov AA; Khaydukov EV; Lopatukhina EV; Semkina AS; Vlasova KY; Sypalov SA; Erofeev AS; Gorelkin PV; Vaneev AN; Nikitina VN; Skvortsov DA; Ipatova DA; Mazur DM; Zyk NV; Sakharov DA; Majouga AG; Beloglazkina EK
    ACS Appl Mater Interfaces; 2023 Mar; 15(10):12882-12894. PubMed ID: 36854172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA Nanostructures as Pt(IV) Prodrug Delivery Systems to Combat Chemoresistance.
    Zhong YF; Cheng J; Liu Y; Luo T; Wang Y; Jiang K; Mo F; Song J
    Small; 2020 Sep; 16(38):e2003646. PubMed ID: 32815274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
    Datta P; Bang S; Yue Z; Beach T; Stilgenbauer M; Wang H; Bowers DJ; Kurokawa M; Xiao H; Zheng YR
    Dalton Trans; 2020 Jun; 49(24):8107-8113. PubMed ID: 32490446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.